Clene (CLNN)
(Delayed Data from NSDQ)
$4.49 USD
+0.16 (3.70%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $4.34 -0.15 (-3.34%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CLNN 4.49 +0.16(3.70%)
Will CLNN be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CLNN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CLNN
Clene Inc. (CLNN) Reports Q1 Loss, Lags Revenue Estimates
Puma Biotech (PBYI) Reports Q1 Loss, Tops Revenue Estimates
CLNN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Clene Inc. (CLNN) Reports Q4 Loss, Tops Revenue Estimates
Dentsply International (XRAY) Q4 Earnings and Revenues Beat Estimates
Amicus Therapeutics (FOLD) Reports Q4 Loss, Lags Revenue Estimates
Other News for CLNN
Optimistic Outlook on Clene’s CNM-Au8 for ALS Amid Anticipated Regulatory Milestones
Clene to Present at the Emerging Growth Conference
Clene Announces Plans to Submit Briefing Book to the U.S. Food and Drug Administration in Connection with Granted Type C Interaction to Obtain FDA Feedback on Potential Pathway to Accelerated Approval for CNM-Au8® in ALS
Clene Announces 1-for-20 Reverse Stock Split
Clene to Present at H.C. Wainwright’s 5th Annual Neuro Perspectives Virtual Conference